Immucell stock analysis
Want to see ICCC full AI Analyst Report?
Immucell (ICCC) Stock Price & Analysis
ICCC Stock Chart & Stats
- Day’s Range
- $11.10 - $11.50
- 52-Week Range
- $4.52 - $12.10
- Previous Close
- $11.25
- Volume
- N/A
- Average Volume (3M)
- 12.96K
- Market Cap
- $101.55M
- Enterprise Value
- $95.21M
- Total Cash (Recent Filing)
- $7.91M
- Total Debt (Recent Filing)
- $12.01M
- Price to Earnings (P/E)
- 55.9
- Beta
- 0.10
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Customer Growth
Broad-based sales and distributor-volume growth indicates stronger product adoption and commercial execution, not merely isolated customer activity. Continued expansion can improve operating leverage, strengthen channel relationships, and provide a durable base for scaling the company’s cattle-health portfolio.
Improved Balance-Sheet Resilience
Meaningfully lower debt and a larger equity cushion improve financial flexibility as the company funds capacity expansion. Reduced leverage should lower balance-sheet pressure and give management more room to absorb operating volatility while investing in commercial growth.
Capacity Expansion Supports Growth
Removing the current drying bottleneck could allow ImmuCell to convert customer demand into higher shipments and revenue over the next several quarters. The planned capacity increase also supports operational scale and reduces dependence on constrained existing production capacity.
Bears Say
Thin And Volatile Profitability
Although the company has returned to profit, modest margins leave limited protection against cost increases or execution setbacks. The history of losses and volatile earnings makes it harder to establish that the recent improvement is durable rather than an early-stage recovery.
Historical Supply And Contamination Issues
Prior contamination-related disruptions demonstrate that production problems can materially affect product availability, customer service, and revenue realization. Even with recovery underway, the episode raises execution risk around maintaining consistent supply as demand and output expand.
Re-Tain Program Failure
Halting Re-Tain removes a development opportunity and leaves the company more reliant on its existing cattle-health products for future growth. The failed trials and manufacturing approval setback also represent sunk development effort without a clear commercial return.
Immucell News
ICCC FAQ
What was Immucell’s price range in the past 12 months?
What is Immucell’s market cap?
When is Immucell’s upcoming earnings report date?
How were Immucell’s earnings last quarter?
Is Immucell overvalued?
Does Immucell pay dividends?
What is Immucell’s EPS estimate?
How many shares outstanding does Immucell have?
What happened to Immucell’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Immucell?
What is the TipRanks Smart Score and how is it calculated?
Immucell Stock Smart Score
Company Description
Immucell
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- F. Olivier Te Boekhorst
- Employees
- 73
- Website
- immucell.com
- Address
- 56 Evergreen Drive, Portland, ME, 04103, US
Immucell (ICCC) Earnings & Revenues
ICCC Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, characterized by 46% third-quarter revenue growth, improved gross margin, a return to profitability, higher manufacturing output, strong distributor and Tri-Shield growth, and progress on capacity expansion. The company also reported challenges, including historical contamination-related supply issues, rising colostrum-sourcing prices, higher operating expenses, and the unsuccessful Re-Tain development program, but these were outweighed by the reported operating and financial improvements.
View all ICCC earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 11 | 0 | 1 |













